MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
5.08
-0.07
-1.36%
After Hours: 5.09 +0.01 +0.20% 18:30 03/28 EDT
OPEN
5.20
PREV CLOSE
5.15
HIGH
5.34
LOW
5.06
VOLUME
3.49M
TURNOVER
0
52 WEEK HIGH
9.07
52 WEEK LOW
4.815
MARKET CAP
1.05B
P/E (TTM)
-4.3098
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BCRX last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at BCRX last week (0311-0315)?
Weekly Report · 03/18 09:03
Weekly Report: what happened at BCRX last week (0304-0308)?
Weekly Report · 03/11 09:03
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
BioCryst Pharmaceuticals (NASDAQ:BCRX investor three-year losses grow to 54% as the stock sheds US$74m this past week
BioCryst Pharmaceuticals, Inc. Shareholders have had a rough ride in the last three years. The share price is down 54% in that time, and is down 6.1% in the past week. The company grew revenue at 56% per year over the past three years, but the share price has fallen 16%. We look at the business performance of the company to see if there are red flags.
Simply Wall St · 03/05 10:57
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. Granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares of common stock. The options and RSUs were granted as of February 29, 2024, as inducements to each employee entering into employment with the company.
Barchart · 03/05 06:01
Weekly Report: what happened at BCRX last week (0226-0301)?
Weekly Report · 03/04 09:03
New Regulation Risk for BioCryst Pharmaceuticals – What’s the Latest?
TipRanks · 02/29 06:00
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers and commercializes oral, small-molecule medicines. The Company focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.